This finding is consistent with studies in colorectal cancer, where TIMP1 knockdown sensitized cells to sorafenib-induced ferroptosis (25, 26, 29), and breast cancer, where TIMP1 expression correlated with chemoresistance (42, 43). This evidence concerns the gene TIMP1 and breast cancer.